(HealthDay News) — In prostate cancer, patient- and clinician-based cumulative toxicity scores comprising all-grade adverse events (AEs) better reflect the impact on patient quality of life (QoL) than scores comprising high-grade AEs only, according to a study published in the Journal of the National Comprehensive Cancer Network.
Claudia S.E.W. Schuurhuizen, MD, from the VU University Medical Center in Amsterdam, and colleagues examined the impact of patient- and clinician-reported cumulative toxicity on QoL among 184 patients with metastatic castration-naive prostate cancer. Patients completed questionnaires on AEs at 3 and 6 months and QoL at baseline, 3 months, and 6 months. During clinical visits, clinicians reported AEs.
The researchers observed an association for clinician-reported all-grade AEs and severity score with deteriorated physical QoL (B, −2.2 and −1.4, respectively), while no correlation was seen for the total number of high-grade AEs. Significant associations were seen for all patient-reported scores with deteriorated physical and global QoL. Patient-reported toxicity scores correlated more with QoL outcomes than did clinician-reported scores; the strongest association was seen for all-grade AEs and severity scores as well as cumulative toxicity scores.
“These patient-reported outcomes appear to have a better correlation to patient quality of life,” Schuurhuizen said in a statement. “Our results also suggest that clinicians shouldn’t lose sight of lower-grade adverse events. We want physicians to be more aware of how addressing lower-grade toxicities can be just as important as higher ones for optimizing physical health status.”
Schuurhuizen C, Marino, P, Braamse A, et al. Impact of Patient- and Clinician-Reported Cumulative Toxicity on Quality of Life in Patients With Metastatic Castration-Naïve Prostate Cancer. J Natl Compr Canc Netw 2018;16:1481-1488. DOI:10.6004/jnccn.2018.7069.